Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
31.98
+2.64 (9.00%)
Apr 29, 2026, 4:08 PM HKT

HKG:3378 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Net Income
--115.83-76.06
Depreciation & Amortization
-5.371.01
Other Amortization
-0.110.03
Loss (Gain) From Sale of Investments
--1.6233.1
Stock-Based Compensation
-22.3515.49
Other Operating Activities
--7.28-20.62
Change in Accounts Payable
--0.640.88
Change in Other Net Operating Assets
--7.35-5.83
Operating Cash Flow
--104.89-51.99
Capital Expenditures
--6.21-4.23
Sale (Purchase) of Intangibles
---0.55
Investment in Securities
-99.9194.63
Other Investing Activities
-2.924.11
Investing Cash Flow
-96.6293.96
Long-Term Debt Repaid
--3.81-1.16
Net Debt Issued (Repaid)
--3.81-1.16
Issuance of Common Stock
-12.8491.38
Other Financing Activities
--2.55-
Financing Cash Flow
-6.4990.22
Foreign Exchange Rate Adjustments
-10.03
Net Cash Flow
--0.79132.21
Free Cash Flow
--111.1-56.23
Free Cash Flow Margin
--5052.48%-2214.49%
Free Cash Flow Per Share
--10.16-7.71
Cash Income Tax Paid
-5.812.05
Levered Free Cash Flow
-101.65-
Unlevered Free Cash Flow
-107.51-
Change in Working Capital
--7.99-4.95
Source: S&P Capital IQ. Standard template. Financial Sources.